Tuesday, July 26, 2022 6:50:52 PM
https://www.washoecourts.com/Query/CaseInformation/CV21-00906
Unfortnately GVSI can't seem to get current through the SEC or OTCIQ.
$GOFF $SRNW $GVSI update (kind of). I hate posting this, but I got to get y'all off my back. Fins for these tickers are ready. Waiting for access to OTCIQ portal. Spoke with Issuer Serv's at OTCM & they are piled on. Entire army working on apps & expect 4-6 weeks from submission
— George Sharp - Advocate for truth in the OTC (@GeorgeASharp) July 27, 2021
We never heard from Sharp after the 4-6 week waitng period concerning GVSI's OTCIQ application. Sharp simply avoided all communication about GVSI for almost a year and never disclosed the result of GVSI's OTCIQ application which looma like it was denied. That's why GVSI continues to be stuck in expert market and can't be traded in the US because the SEC won't allow it.
Today, my attorney is filing for custodianship of $GVSI on my behalf. Those buying shares must know that there is incredible risk here. My application could be denied. I could find really bad skeletons.
— George Sharp - Advocate for truth in the OTC (@GeorgeASharp) April 19, 2021
Do not ask me questions regarding the progress. You will be blocked
Sharp NEVER gave a warning like this for GOFF/WNFT and SRNW. Now they are both current while GVSI is still stuck in expert market while it keeps getting denied becoming current by the SEC and OTCIQ.
Today, my attorney is filing for custodianship of $GVSI on my behalf. Those buying shares must know that there is incredible risk here. My application could be denied. I could find really bad skeletons.
— George Sharp - Advocate for truth in the OTC (@GeorgeASharp) April 19, 2021
Do not ask me questions regarding the progress. You will be blocked
Luckily EVLI isn't in expert market and is trading with no restrictions and will continue to do so as long as Sharp continues his custodianship court case. A case where Sharp has the advantage and can easily outspend Blankenship to gain control of EVLI.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM